Latest news with #MorgansFinancial
SBS Australia
11-07-2025
- Business
- SBS Australia
Albanese trip to China could be good for both nations' economies
Financial experts say Prime Minister Anthony Albanese's visit to China will provide an economic boost for both countries. Mr Albanese leaves tomorrow on a trip that includes stops in Beijing, Shanghai and Chengdu and will meet senior Chinese leaders, including President Xi Jinping. Mr Albanese will be accompanied by an Australian business delegation. China is Australia's largest trading partner, and, after a period of frosty relations, has removed around 200 billion dollars worth of trade restrictions on Australia in recent years Raymond Chan, Head of the Asian Desk at Stockbroking Wealth Management firm Morgans Financial Limited, tells S-B-S Cantonese Mr Albanese's visit is another indication of the renewed sense of certainty in the Australia-China relationship. "This visit is seen as a positive signal because one thing important in the world of investing is certainty. When the bilateral relationship is uncertain, investors will hesitate to invest. With a more stable relationship between Australia and China it certaintly boosts sentiment. It's especially important for China because China is Australia's largest trading partner." The Australian Competition and Consumer Commission has set up a unit to target romance scams, as reports of the scam types grow. Known as a 'fusion cell', the unit will bring together dating and social media industry representatives as well as law enforcement and financial institutions to better understands and disrupt the scams. Australians lost over $23 million to romance scams last year, with people from a culturally or linguistically diverse background, those with a disability, and First Nations Australians disproportionately impacted by the scams. ACCC Deputy Chair Catriona Lowe tells S-B-S people are at risk when looking for love. "These criminals are experts at targeting really lovely parts of human nature. There is nothing wrong, obviously, with wanting a new relationship, and so people who are seeking that sort of relationship are vulnerable to these sorts of scams." Police say a German backpacker who has been missing for two weeks in Western Australia's wheat belt, likely got lost in dense bushland after her car broke down. W-A police have escalated a national search for 26 year-old Carolina Wilga yesterday, after her van was discovered about 100 kilometres north of where she was last seen in the small Wheatbelt town of Beacon. Carolina was last seen on the 29th of June. Police say the van appears to have suffered mechanical issues. Police are urging a motorbike rider who allegedly ran over a nine-year-old girl in southwest Sydney to come forward. Last night, police say the girl was playing with her friends in the park in the suburb of Rosemeadow when a rider on an unregistered dirt bike came roaring over a hill, hitting the young girl. She was treated for facial injuries by paramedics at the scene and was taken to Westmead Children's Hospital in a serious condition. New South Wales Police Detective Superintendent Grant Healey says police don't believe the incident was intentional but the rider needs to do right by the girl and turn himself in. "Police are actually seeking the rider of the bike to do the right thing and come into the police station and hand themselves in. The rider would know that he hit the little girl. He did stop briefly and had a really brief conversation and rode off without helping the young child. For him to do the right thing by the little girl is to come and hand himself in to police." US Secretary of State Marco Rubio has met with his counterparts in Southeast Asia, seeking to reassure them about the region's importance to the Trump administration, amid the fallout from US tariffs. Mr Rubio joined foreign ministers of the 10-member Association of Southeast Asian Nations in Kuala Lumpur at a meeting that includes Australia, China, the European Union, Japan, Russia, South Korea and others. The delegates have spoken about the threats facing the region as a result of these tariffs, while Russia and China are pushing for deeper ties amid the tariff resentment. Mr Rubio says the Trump administration considers the Indo-Pacific a focal point of its foreign policy. 'We're not abandoning those relationships. On the contrary, we want to strengthen and build upon them. And there are a bunch of other issues, and certainly trade is part of it. But there are a lot of other issues that we work together on. And we will continue to highly prioritise that. The story of the 21st century will be written in the Indo-Pacific. And the countries represented here today along with others that have joined to be a part of this, represent some not just important markets, some of the most important partners we have in the world." In cricket, Australian fast bowler Mitchell Starc says fellow fast bowlers Josh Hazlewood and Pat Cummins deserve much of the credit for his success. 35-year-old Starc will become just the second Australian fast bowler, after Glenn McGrath, to play 100 Test matches when he plays for Australia in the third Test against the West Indies in Jamaica, which starts on Sunday morning [[13th July]]. Starc, Hazlewood, and Australian captain Cummins all hail from New South Wales, and have played a lot of cricket together. Starc says the trio have lifted one another at the sport's highest level. "It's not lost on myself, or the three of us, how lucky I think we are that we are all from the same place- we train together, we sit in rehab rooms together. Over the years, the ability to push each other along the way, whether it's a flat week or a Test week... I think that contributes to the longevity of the three of us in particular."
Daily Telegraph
06-07-2025
- Business
- Daily Telegraph
Stock Tips: An iron giant makes its presence felt
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. It's no easy gig analysing share prices and company performance but somebody's got to do it. Every week two experts from our Share Tips columnist pool give us their recommendations. Andrew Eddy – Morgans Financial BUY Minerals 260 (MI6) Offers significant gold resource growth potential, clear M&A appeal and a path to production. Not without risk but see significant upside potential. Motorcycle Holdings (MTO) Has acquired profitable dealerships, expanded into new markets and strengthened its e-commerce capabilities, positioning itself for significant growth. HOLD Transurban Group (TCL) Offers stable returns with high-quality toll road assets, driven by population growth, economic development and strong pricing power through toll escalations James Hardie (JHX) The highest quality building products business on the ASX, with strong returns on capital and a dominant market position – just need to see an improving housing outlook in the US to become more bullish. SELL Santos (STO) Investors might consider taking some money off the table with Santos with limited upside to bid price but there are significant risks and hurdles for a deal to be completed. Cochlear (COH) Company recently downgraded guidance on slower growth in services and Cochlear Implant uptake, still a quality stock but further downside earnings risks remain. Dylan Evans – Catapult Wealth BUY CSL Ltd (CSL) The uncertain trade and tariff environment provides an opportunity to purchase a business reporting double digit earnings growth at a compelling price. RIO Tinto (RIO) RIO has exposure to iron ore, aluminium, copper and lithium. Iron ore is unlikely to offer growth moving forward, but the remaining areas of the business play into attractive themes, particularly the growing demand for electricity, batteries, and other technologies. HOLD Technology One (TNE) Australia's leading enterprise software company has been delivering fantastic results with consistent momentum. TNE hit its $500m annual recurring revenue target in May, 18 months ahead of schedule, and the company is now targeting $1bn by 2030. Virgin Australia (VGN) Virgin's return to the ASX is well timed, against a favourable backdrop of lower fuel prices and falling rates. With that said we are cautious of owning airlines for any long period, being a cyclical industry with a history of insolvencies and administrations. SELL BlueScope Steel (BSL) While BlueScope's move into downstream construction markets is positive, the underlying business operates in a low margin industry heavily reliant on volatile energy costs and steel prices. Washington H Soul Pattinson (SOL) Washington Soul Pattinson recently announced a merger with Brickworks (BKW), two companies with a long history of cross-ownership. The merger makes sense, but the share price has rallied considerably. The views, information, or opinions expressed in the interviews in this article are solely those of the interviewees and do not represent the views of Stockhead. Stockhead does not provide, endorse or otherwise assume responsibility for any financial advice contained in this article. Originally published as Stock Tips: An iron giant and a biotech behemoth make their presence felt
News.com.au
06-07-2025
- Business
- News.com.au
Stock Tips: An iron giant and a biotech behemoth make their presence felt
It's no easy gig analysing share prices and company performance but somebody's got to do it. Every week two experts from our Share Tips columnist pool give us their recommendations. Andrew Eddy – Morgans Financial BUY Minerals 260 (MI6) Offers significant gold resource growth potential, clear M&A appeal and a path to production. Not without risk but see significant upside potential. Motorcycle Holdings (MTO) Has acquired profitable dealerships, expanded into new markets and strengthened its e-commerce capabilities, positioning itself for significant growth. HOLD Transurban Group (TCL) Offers stable returns with high-quality toll road assets, driven by population growth, economic development and strong pricing power through toll escalations James Hardie (JHX) The highest quality building products business on the ASX, with strong returns on capital and a dominant market position – just need to see an improving housing outlook in the US to become more bullish. SELL Santos (STO) Investors might consider taking some money off the table with Santos with limited upside to bid price but there are significant risks and hurdles for a deal to be completed. Cochlear (COH) Company recently downgraded guidance on slower growth in services and Cochlear Implant uptake, still a quality stock but further downside earnings risks remain. Dylan Evans – Catapult Wealth BUY CSL Ltd (CSL) The uncertain trade and tariff environment provides an opportunity to purchase a business reporting double digit earnings growth at a compelling price. RIO Tinto (RIO) RIO has exposure to iron ore, aluminium, copper and lithium. Iron ore is unlikely to offer growth moving forward, but the remaining areas of the business play into attractive themes, particularly the growing demand for electricity, batteries, and other technologies. HOLD Technology One (TNE) Australia's leading enterprise software company has been delivering fantastic results with consistent momentum. TNE hit its $500m annual recurring revenue target in May, 18 months ahead of schedule, and the company is now targeting $1bn by 2030. Virgin Australia (VGN) Virgin's return to the ASX is well timed, against a favourable backdrop of lower fuel prices and falling rates. With that said we are cautious of owning airlines for any long period, being a cyclical industry with a history of insolvencies and administrations. SELL BlueScope Steel (BSL) While BlueScope's move into downstream construction markets is positive, the underlying business operates in a low margin industry heavily reliant on volatile energy costs and steel prices. Washington H Soul Pattinson (SOL) Washington Soul Pattinson recently announced a merger with Brickworks (BKW), two companies with a long history of cross-ownership. The merger makes sense, but the share price has rallied considerably.
AU Financial Review
02-07-2025
- Business
- AU Financial Review
Bids due for $400m Advanced Innergy float; IPO date set
Morgans Financial is calling for bids for Advanced Innergy Holdings, the protection products manufacturer that's making its way to the ASX, after finalising key valuation metrics on Wednesday. Street Talk can reveal Advanced Innergy Holdings (AIS) has priced its initial public offering at $1 per share, with around 200 shares on offer. With existing owners holding another 200 shares, this will give AIS a market capitalisation of $404 million and a 52.1 per cent free float on listing.
News.com.au
20-06-2025
- Business
- News.com.au
Scott Power: ASX health stocks fall in ‘lacklustre week'
ASX heath sector falls 1.1% over past five days The US FDA approves CSL's Andembry to prevent attacks of hereditary angioedema Clever Culture systems records its second consecutive quarter of positive cashflow operations Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. The ASX healthcare sector has had what Morgans' senior healthcare analyst Scott Power described as a "lacklustre week". At lunchtime on Friday, the S&P/ASX 200 Health Care index (ASX:XHJ) was down 1.1% for the past five days, while the benchmark S&P/ASX 200 (ASX:XJO) fell 0.55% for the same period. Markets have been influenced by global economic and geopolitical concerns, particularly escalating tensions between Iran and Israel. And it seems US President Donald Trump has not backed down from tariffs on pharmaceutical imports. A United States Department of Commerce investigation is underway under Section 232 of the Trade Expansion Act of 1962 – a provision that allows the president to restrict imports if they are deemed a threat to national security. Returning from the G7 Summit in Canada Trump reportedly told media on Air Force One tariffs on the sector were coming. "We're going to be doing pharmaceuticals very soon," he said. "That's going to bring all the companies back into America... at least partially back in." Power said Trump's latest comments were adding further jitters to the sector. "Until we get clarity there's going to be volatility," he said. Power's Powerplay – CSL gets FDA approval for Andembry The ASX's largest healthcare stock CSL (ASX:CSL) has notched a milestone with the FDA approving its Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE). Affecting about one in 50,000 people CSL said HAE was the first and only treatment targeting factor XIIa for prophylactic use to provide sustained protection from attacks of HAE in adult and pediatric patients aged 12 years and older. The approval was based on a pivotal phase III (VANGUARD) trial and ongoing open-label extension study, showing Andembry reduced the median number of HAE attacks by more than 99% (mean 89.2%), compared to placebo. Andembry is also the only treatment to offer once-monthly dosing from the start for all patients and is administered via an autoinjector. The drug is already available in Australia, the UK, EU, Japan, Switzerland and UAE. CSL said Andembry will be launched "immediately", with availability through third-party specialty pharmacy network before the end of June. In a note to clients, Morgans' healthcare analyst Derek Jellinek wrote that while Andembry's US approval had taken longer than expected, with application filing in December '24, it's good to see the drug greenlit before the end of '25 "despite the ongoing tumultuous environment" at the US Food and Drug Administration at the agency. "We view Andembry's unique MOA (ie upstream inhibition of key pathways leading to HAE attacks, so broader applicability), favourable safety profile and convenient dosing (every 4 weeks via subcutaneous injection) as key differentiators," Jellinek wrote. While Andembry is expected to impact Berinert sales – CSL's treatment for acute HAE attacks – Jellinek believes the effect should be modest. He wrote Berinert's revenue was forecast to remain steady in FY25 at US$242 million, accounting for less than 2% of CSL's total revenue. Sales are projected to ease slightly to US$230m in FY26 and US$225 million in FY27. However, this is more than compensated by anticipated growth in Andembry sales, which are expected to reach US$120m in FY26 and increase to US$220m in FY27. Morgans has an add rating on CSL and 12-month target price of $329.26. Clever Culture Systems delivers clever Q3 FY25 result Clever Culture Systems (ASX:CC5) has achieved its second consecutive quarter of positive cashflow operations with $500,000 net cash inflow in Q3 FY25 and is on track to achieve break-even or better for H2 FY25. During the quarter Clever Culture continued to execute on its commercialisation strategy for its APAS Independence instruments in the pharmaceutical market, building on success with big pharma companies Astra Zeneca and Bristol Myers Squibb (BMS). The instruments use artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. Since launching the product in March 2024, Clever Culture said it had completed sales and received orders from pharmaceutical customers for 13 APAS instruments, representing ~$6 million in revenue with a pipeline of 40 qualified opportunities. Clever Culture finished Q3 FY25 with a cash position of $2.2m. "Other top 10 pharmaceutical companies are expected to engage with CC5 following the AstraZeneca and Bristol Myers Squibb success," Power said. Emvision awarded $5 million government grant EMVision Medical Devices (ASX:EMV) has been awarded a $5 million federal government grant to further development of its First Responder portable brain scanner. The funds are by way of an Australian government Industry Growth Program (IGP) Commercialisation and Growth Grant. First Responder is EMVision's second product and distinguishes between bleed and clot strokes at the scene and is designed to be used by ambulances and by paramedics. The device should shorten diagnosis time, a crucial element in the patient getting the right treatment. EMVision's first commercial device – the emu bedside brain scanner – is also designed to rapidly diagnose stroke at the point-of-care with a pivotal trial underway to supports US Food and Drug Administration (FDA) de novo (new device) clearance. Audeara hits record, Micro-X gets milestone payment boost In other news of the week, specialist in listening solutions for people with hearing challenges Audeara (ASX:AUA) has delivered record revenue exceeding $3.64 million for the 11 months to end of May FY25. Audeara reported revenue for the 11-month period was up 14% on FY24 total revenue and 25% on FY23, which the company said signalled underlying strength of its ongoing operations. The company expects additional growth to materialise in coming weeks based on strong June 2025 trading. And leader in cold cathode x-ray technology for health and security markets Micro-X (ASX:MX1) has received $2.3 million in milestone payments for two projects. MicroX achieved milestone three under its development agreement with US Advanced Research Projects Agency for Health (ARPA-H) and Department of Homeland Security (DHS) for a full body CT scanner, delivering $1.4 million. The company also achieved milestone two under a strategic partnership deal with Billion Prima for a baggage and parcel scanning unit due for completion in 2025, delivering $900,000. "We are pleased to continue to deliver strong progress on these key development contracts with ARPA-H, DHS, and Billion Prima respectively, which is a testament to our focus and timely delivery on key projects," Micro-X CEO Kingsley Hall said. "We are also well advanced with the final stages of our Head CT development as we prepare to enter human imaging trials." The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Clever Culture Systems, Audeara and EMVision are Stockhead advertisers, the companies did not sponsor this article.
